Chia Tai Fenghai Licenses FHND5032 miR-124 Inducer to Formation Bio for $500 Million
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) has entered a strategic licensing agreement with...
Chia Tai Fenghai Pharmaceutical
GCCF and CTTQ Explore Collaboration to Expand Innovative Drug Access in Hong Kong
Dr. Cheng Kam-chung, Founder and Chairman of the Greater China Cancer Foundation (GCCF), led a...
Jiangsu Chia Tai Fenghai’s ALS Treatment FHND1002 Selected for CDE’s Patient-Centered Care Plan
China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai...